On August 3, CMS finalized future effective guidelines for the use of tissue products on chronic lower extremity ulcers for Local Coverage Determinations (LCD).
For dates of service on or after October 1, 2023
Total number of Medicare beneficiaries in these states: approximately 13 million
Decrease in Number of Applications per Episode of Care (EoC)
12-Week Episode of Care
JW and new JZ Modifier
Kerecis CTP products remain covered by these MACs, including:
Kerecis was cited on two accounts as part of the rationale behind the CMS guideline changes.
“A fortieth commenter asserts that while they agree that not all wounds require the current allotted amount of 10 grafts in a 12-week episode, most wounds require more than two applications. In Kerecis clinical studies, the average number of applications until complete wound closure is 4.5 grafts.” The study referenced is by Dr. Michael et al. on diabetic foot ulcers, which saw an average of 4.5 applications used to achieve healing. (PMID: 31730505)
“A third commenter indicates that many wounds do not heal within 12 weeks. Kerecis has numerous case studies demonstrating wound closure, over the course of 6-12 months, utilizing grafts as needed rather than squeezing as many in as possible in the short time frame allowed. Most of these case studies utilized only five or less grafts over a longer period of time.”
Feel free to reach out to email@example.com or your local Kerecis representative with any questions.